By Reuters Staff
August 22, 2019
NEW YORK (Reuters Health) - The direct-acting antiviral (DAA) combination of glecaprevir and pibrentasvir is effective in patients with genotype 1 hepatitis C virus (HCV) infection after failure of treatment with sofosbuvir plus an NS5A inhibitor, according to results from a new open-label trial.
The combination of ...
Map of Hepatitis C in Asia
No matching locations Show all locations
No location found Show all locations
Latest News
06
Dec
Latest Stories from Patient
09
Mar
My Name is Ayu Oktariani, I’m from Bandung, Indonesia, I am 29 years old female. I’m co-infection HIV HCV patient, since 2009. My HIV condition is very well managed since the time infected, the ARV therapy help me through the difficult time. But my HCV infection makes it harder, because ...
08
Mar
My name is Ajitshwor Wangkheirakpam. I am 42 years old male from Manipur in India. I have been living with HIV and HCV co-infection for a long time. My HIV have been completely well controlled and managed, thanks to the government program for anti-retroviral for HIV. However, my HCV infection ...